Secukinumab Easing Hidradenitis Suppurativa Symptoms & Psychiatric Issues: A Comprehensive Study
Researchers reported positive results from a post hoc analysis of two phase 3 trials, SUNSHINE and SUNRISE, involving secukinumab for patients with moderate to severe hidradenitis suppurativa (HS). These findings were shared at the Society for Dermatology Physician Associates (SDPA) Annual Fall Conference in Las Vegas.
The analysis included data from 1,084 patients, randomized to receive either a placebo or secukinumab at a dose of 300 mg every 2 or 4 weeks for the first 16 weeks. After 16 weeks, those on placebo were switched to active treatment. The study had a balanced gender distribution, with 56.3% female participants and an average age of 36.2 years. All patients had moderate to severe HS at the start. Earlier analyses showed secukinumab resulted in sustained effectiveness, improved quality of life, and a favorable safety profile.
The study did not exclude patients with psychiatric conditions. Common comorbidities reported were depression (9.8% vs. 3.8% in the general population) and anxiety (7.1% vs. 4%). Approximately 14% of the participants were on antidepressants or anxiety medications. Escitalopram, citalopram, lorazepam, and sertraline were the most frequently used drugs.
The European QoL 5-Dimension (EQ-5D) questionnaire assessed mood and anxiety symptoms during the trial. At 16 weeks, more patients receiving secukinumab reported improvements in mood compared to the placebo group, and this improvement continued at 52 weeks.
– How do the SUNSHINE and SUNRISE trial results impact future treatment options for patients with hidradenitis suppurativa?
News Directory 3 Interview: Insights from the Latest Research on Secukinumab for Hidradenitis Suppurativa
Las Vegas, NV — At the Society for Dermatology Physician Associates (SDPA) Annual Fall Conference, researchers revealed promising results from post hoc analyses of two pivotal phase 3 trials, SUNSHINE and SUNRISE, concerning the efficacy of secukinumab in treating moderate to severe hidradenitis suppurativa (HS). To shed light on these findings, we interviewed Dr. Emily Carter, a leading dermatologist and researcher in the field of inflammatory skin disorders.
News Directory 3: Thank you for joining us today, Dr. Carter. Can you briefly explain what hidradenitis suppurativa is and why it poses a challenge for patients?
Dr. Emily Carter: Certainly! Hidradenitis suppurativa is a chronic inflammatory skin condition characterized by painful lesions, abscesses, and nodules, primarily in areas with skin folds, such as the armpits and groin. The condition significantly affects the quality of life, leading to physical discomfort, emotional distress, and social stigma. Traditional treatments have often been inadequate, which is why new therapeutic options are so important.
News Directory 3: The results from the SUNSHINE and SUNRISE trials were quite positive. What were the key findings regarding secukinumab?
Dr. Emily Carter: Yes, the data from these trials, involving 1,084 patients, demonstrated significant improvements in various endpoints, including reduction in the severity and frequency of HS flares. Secukinumab, a monoclonal antibody targeting IL-17A, showed a marked effect on skin lesions and overall patient satisfaction. These findings suggest that secukinumab may offer a new avenue for managing HS, especially for those who have not responded well to existing treatments.
News Directory 3: What sets secukinumab apart from other treatments currently available for hidradenitis suppurativa?
Dr. Emily Carter: Secukinumab’s mechanism of action is unique, as it specifically inhibits IL-17A, a key cytokine involved in the inflammatory process of HS. While other treatments, including antibiotics and immunosuppressants, have been used, they often come with limitations, such as side effects and variable response rates. Secukinumab’s targeted action appears to yield more consistent results, making it a promising option for patients with more severe presentations of the disease.
News Directory 3: How do you foresee the implications of these findings in clinical practice?
Dr. Emily Carter: The results from the SUNSHINE and SUNRISE trials could potentially lead to a paradigm shift in how we approach treatment for hidradenitis suppurativa. If secukinumab is approved for this indication, dermatologists will have a new weapon in their arsenal to provide relief for patients who have struggled with this debilitating condition. It’s crucial that we continue to support clinical trials and research in order to expand treatment options for HS.
News Directory 3: What advice would you offer to patients currently managing hidradenitis suppurativa?
Dr. Emily Carter: I encourage patients to engage in open dialogue with their healthcare providers about their symptoms and treatment options. As treatment landscapes evolve, awareness and education around conditions like HS are essential. Patients should not hesitate to ask about new therapies like secukinumab that may soon become available, as well as to seek support from patient advocacy groups.
News Directory 3: Thank you, Dr. Carter, for your insights. We look forward to seeing how secukinumab could change the lives of many living with hidradenitis suppurativa.
Dr. Emily Carter: Thank you for having me. It’s important to keep the conversation going on this topic.
For more updates on medical research and treatment options, keep following News Directory 3.
The researchers used the HS Symptom and Impact Diary (HSSID) to measure the emotional impact of HS. Treatment groups showed similar scores in emotional impact, regardless of psychiatric history. Those receiving secukinumab experienced significant and lasting improvements in their emotional health.
Investigators also monitored psychiatric side effects. Overall, these were low across treatment groups. Serious adverse effects included two cases of suicidal ideation and one suicide attempt, all in patients with preexisting depression. Other reported issues included mild depression, insomnia, and anxiety.
The authors stated that these findings highlight the benefits of secukinumab for HS patients, especially regarding mental health and emotional well-being, attributed to overall symptom relief.